Discovery and Characterization of Benzamide Derivatives as Highly Potent SUCNR1 Antagonists for Cancer Immunotherapy
Journal of Medicinal Chemistry · 25.06.2026 · 69 (12) · 14174-14190
DOI: 10.1021/acs.jmedchem.5c03465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.05.2026. Verfasst von Zhiyuan Cheng und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Discovery & Translational Medicine, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou 571199, China. Hauptthemen laut MEDLINE: Benzamides, Immunotherapy, Antineoplastic Agents, Drug Discovery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: the Open Research Fund of Key Laboratory of Cancer Prevention and Intervention (Zhejiang University), Ministry of Education and Fundamental Research Funds for…, the Innovative Drug Research and Development National Science and Technology Major Project.
Abstract (Originalsprache)
Targeting the succinate receptor 1 (SUCNR1), a key metabolic checkpoint in the tumor microenvironment, emerges as a promising strategy for cancer immunotherapy. Herein, we identified a weak benzamide-based hit compound (5) through an internal library screening. A systematic structure-activity relationship (SAR) exploration then yielded compound 26, which exhibited low-nanomolar SUCNR1 antagonistic activity in multiple cell functional assays. Molecular dynamics simulations revealed that the methoxy group of 26 forms stable, water-bridged hydrogen bonds with the key residue Glu221.31. Notably, 26 effectively reversed succinate-mediated immunosuppression in macrophages by abrogating the expression of multiple immunosuppression-related genes. In the patient-derived tumor immune organoid models, 26 triggered a robust antitumor immune response, marked by a reduction in immunosuppressive macrophages and a concomitant expansion of cytotoxic T cells. Thus, our work not only establishes 26 as a lead candidate for targeting SUCNR1 but also provides compelling evidence for SUCNR1 antagonism as a potent therapeutic approach in immuno-oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Drug Discovery & Translational Medicine, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou 571199, China.
- Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, Hainan Provincial Key Laboratory for Research and Development of Tropical Herbs and Haikou Key Laboratory of Li Na…
- Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China.
- Research Center for Medicinal Structural Biology, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medic…
- Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450052, China.
- Department of General Surgery and Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200020, China.
ORCID-Profile: Zhiyuan Cheng, Linlin Yang, Mingyao Liu, Weiqiang Lu
Förderung
- the Open Research Fund of Key Laboratory of Cancer Prevention and Intervention (Zhejiang University), Ministry of Education and Fundamental Research Funds for…
- the Innovative Drug Research and Development National Science and Technology Major Project
Zitieren
APA
Cheng, Z., He, J., Li, C., Quan, K., Du, L., Chai, X., Yang, X., Abuduaini, N., Fu, Y., Sun, J., Zhang, S., Feng, B., Wu, D., Rui, W., Xu, H. E., Yang, L., Liu, M., & Lu, W. (2026). Discovery and Characterization of Benzamide Derivatives as Highly Potent SUCNR1 Antagonists for Cancer Immunotherapy. Journal of Medicinal Chemistry, 69(12), 14174-14190. https://doi.org/10.1021/acs.jmedchem.5c03465
Vancouver
Cheng Z, He J, Li C, Quan K, Du L, Chai X, et al. Discovery and Characterization of Benzamide Derivatives as Highly Potent SUCNR1 Antagonists for Cancer Immunotherapy. Journal of Medicinal Chemistry. 2026;69(12):14174-14190. doi:10.1021/acs.jmedchem.5c03465
BibTeX
@article{Cheng2026,
author = {Cheng, Zhiyuan and He, Jiacheng and Li, Changyao and Quan, Ke and Du, Limin and Chai, Xiaolei and Yang, Xinyu and Abuduaini, Naijipu and Fu, Yuanyuan and Sun, Jing and Zhang, Sen and Feng, Bo and Wu, Deyan and Rui, Weiwei and Xu, H Eric and Yang, Linlin and Liu, Mingyao and Lu, Weiqiang},
title = {Discovery and Characterization of Benzamide Derivatives as Highly Potent SUCNR1 Antagonists for Cancer Immunotherapy},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {12},
pages = {14174--14190},
doi = {10.1021/acs.jmedchem.5c03465}
}
EUVIMED